Architect bnp jp

We measured blood cell count, Alb, blood urea nitrogen, creatinine, eGFR, Zn, and Cu. Serum Zn and Cu levels were measured by atomic absorption spectrophotometry (Z6100, Hitachi Power Solutions Co., Ltd., Ibaraki, Japan) (23 (link), 24 (link)). eGFR was calculated using the revised equation adjusted for the Japanese population (25 (link)). We also measured PG, hemoglobin A1c (HbA1c), B-type natriuretic peptide (BNP), serum total cholesterol, triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and insulin levels. Low-density lipoprotein cholesterol (LDL-C) levels were calculated using the Friedewald formula (26 (link)). Plasma BNP levels were measured using a specific immunoradiometric assay for human BNP (ARCHITECT BNP-JP^®, ABBOTT JAPAN Co., Ltd., Tokyo, Japan).

All the patients were required to provide baseline plasma samples before HD session on the day underwent HD session, including hemoglobin, hemoglobin A1c, cholesterol profiles, BNP, high‐sensitive cTnT (hs‐cTnT), and high‐sensitive CRP (hs‐CRP). The samples were centrifuged within 60 minutes and stored at −80°C for further analysis. hs‐cTnT was measured by an electro chemiluminescence immunoassay (ECLIA) with the EClusys hs‐cTnT Roche diagnostic assay. In the hs‐cTnT assay, the 99th percentile of the upper reference limit and the lower limit of detection were 0.014 and 0.003 ng/mL, respectively. BNP was measured with a specific immunoradiometric assay for human BNP (ARCHITECT BNP‐JP; ABBOTT JAPAN Co, Ltd, Tokyo, Japan). The inter‐ and total coefficient variation for BNP was 1.1% to 5.1% and 2.3% to 5.3%, respectively. Hs‐CRP was measured using N‐latex CRP II (Dade Behring Inc., Marburg, Germany) with a coefficient variation of 3.1% at 0.5 mg/L.